1027950-57-7

Basic information

• Product Name: [2-(N'-acetyl-N'-methyl-hydrazino)-1-benzyl-2-oxo-ethyl]-methyl-carbamic acid tert-butyl ester
• CAS NO: 1027950-57-7
• Molecular Weight: 349.43
• Mol File: 1027950-57-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: [2-(N'-acetyl-N'-methyl-hydrazino)-1-benzyl-2-oxo-ethyl]-methyl-carbamic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: [2-(N'-acetyl-N'-methyl-hydrazino)-1-benzyl-2-oxo-ethyl]-methyl-carbamic acid tert-butyl ester(1027950-57-7)
• EPA Substance Registry System: [2-(N'-acetyl-N'-methyl-hydrazino)-1-benzyl-2-oxo-ethyl]-methyl-carbamic acid tert-butyl ester(1027950-57-7)

Safety Data

• Hazardous Substances Data: 1027950-57-7(Hazardous Substances Data)

Upstream product

• 3530-13-0 N-methylacetohydrazide 
• 37553-65-4 N-tert-butoxycarbonyl-N-methyl-D-phenylalanine 

Downstream Products

• 232615-09-7 {4-[(1-{[2-(N'-acetyl-N'-methyl-hydrazino)-1-benzyl-2-oxo-ethyl]-methyl-carbamoyl}-2-naphthalen-2-yl-ethyl)-methyl-carbamoyl]-1,1-dimethyl-but-3-enyl}-carbamic acid tert-butyl ester 
• 1027078-51-8 (1-{[2-(N'-acetyl-N'-methyl-hydrazino)-1-benzyl-2-oxo-ethyl]-methyl-carbamoyl}-2-naphthalen-2-yl-ethyl)-methyl-carbamic acid tert-butyl ester 
• 232615-08-6 N-[2-(N'-acetyl-N'-methyl-hydrazino)-1-benzyl-2-oxo-ethyl]-N-methyl-2-methylamino-3-naphthalen-2-yl-propionamide 

Relevant articles and documents

Growth hormone secretagogues derived from NN703 with hydrazides as C- terminal

A series of GH secretagogues based on modifications in the C-terminal of NN703 is reported. The C-terminal N-methyl amide of NN703 has been replaced with alkylated hydrazides in order to decrease the volume of distribution and identify GH secretagogues with shorter duration of action. Most of the prepared compounds show high potency in a rat pituitary assay. Subsequent to an initial in vivo screening in dogs, four compounds were selected for further pharmacological and pharmacokinetic evaluation. The four compounds showed oral bioavailability around 35% and equipotency in vitro compared to NN703. The relationship between lipophilicity and volume of distribution is discussed and it is speculated whether the lower volume of distribution is attributed to the observed higher in vivo potency and shorter plasma elimination half-life. (C) 2000 Editions scientifiques et medicales Elsevier SAS.